Journal: Neurobiology of Pain

Article Title: Xpro®1595 alleviates neuropathic pain by targeting spinal dorsal horn ADAM17-mediated inflammation ☆

doi: 10.1016/j.ynpai.2026.100210

Figure Lengend Snippet: Schematic of the experimental timelines. (A) Timeline for behavioral testing following a single intrathecal injection of recombinant ADAM17 (re-ADAM17) or bovine serum albumin (BSA) vehicle in naïve rats. (B) Timeline for behavioral testing and tissue collection in spinal nerve ligation (SNL) rats following repeated intrathecal administration of Xpro®1595 or saline vehicle. Arrows indicate injection time points.

Article Snippet: Xpro®1595 (Xencor Corporation, Monrovia, CA, USA) was dissolved in sterile saline to working concentrations of 0.1, 0.15, and 0.2 μg/μL ( ).

Techniques: Injection, Recombinant, Ligation, Saline

Journal: Neurobiology of Pain

Article Title: Xpro®1595 alleviates neuropathic pain by targeting spinal dorsal horn ADAM17-mediated inflammation ☆

doi: 10.1016/j.ynpai.2026.100210

Figure Lengend Snippet: Intrathecal administration of Xpro®1595 attenuates SNL-induced mechanical allodynia and ADAM17 upregulation. (A) Representative Western blot bands showing ADAM17 protein levels in the ipsilateral SDH of sham or SNL rats treated with saline or Xpro®1595 (10 μg/kg) on day 3 post-surgery. (B) Densitometric quantification of ADAM17 protein expression relative to β-actin. (C)Mechanical paw withdrawal thresholds (PWT) in SNL rats following repeated intrathecal injections of Xpro®1595 (10 μg/kg) or saline. Arrows indicate injection time points. (D) Dose-dependent effect of Xpro®1595 (5, 7.5, or 10 μg/kg) on mechanical thresholds at day 5 post-SNL (24 h after the second injection). Data are presented as mean ± SEM. n = 6–8 rats/group. ** p < 0.01 vs. sham group; # p < 0.05 vs. SNL-saline group; One-way ANOVA followed by Tukey’s post hoc test.

Article Snippet: Xpro®1595 (Xencor Corporation, Monrovia, CA, USA) was dissolved in sterile saline to working concentrations of 0.1, 0.15, and 0.2 μg/μL ( ).

Techniques: Western Blot, Saline, Expressing, Injection

Journal: Neurobiology of Pain

Article Title: Xpro®1595 alleviates neuropathic pain by targeting spinal dorsal horn ADAM17-mediated inflammation ☆

doi: 10.1016/j.ynpai.2026.100210

Figure Lengend Snippet: Xpro®1595 suppresses the SNL-induced pro-inflammatory cytokine response in the spinal dorsal horn. (A-C) Representative Western blot bands and corresponding quantification of TNF-α, IL-1β, and IL-6 protein levels in the ipsilateral SDH from sham, SNL + saline, or SNL + Xpro®1595 (10 μg/kg) treated rats at day 3 post-surgery. (D-F) ELISA quantification of TNF-α, IL-1β, and IL-6 protein concentrations in SDH tissue lysates from the same experimental groups. Data are presented as mean ± SEM. n = 6 rats/group. * p < 0.05, ** p < 0.01 vs. sham group; # p < 0.05, ## p < 0.01 vs. SNL + saline group; One-way ANOVA followed by Tukey’s post hoc test.

Article Snippet: Xpro®1595 (Xencor Corporation, Monrovia, CA, USA) was dissolved in sterile saline to working concentrations of 0.1, 0.15, and 0.2 μg/μL ( ).

Techniques: Western Blot, Saline, Enzyme-linked Immunosorbent Assay